• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    BioCryst Pharmaceuticals, Inc. - Common Stock (NQ:BCRX)

    8.110 -0.130 (-1.58%)
    Delayed Quote Updated: 9:37 AM EST, Nov 5, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 203,648
    Open 8.200
    Bid (Size) 8.110 (300)
    Ask (Size) 8.140 (400)
    Prev. Close 8.240
    Today's Range 8.040 - 8.275
    52wk Range 6.230 - 11.22
    Shares Outstanding 185,583,896
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    BioCryst (BCRX) Q3 2026 Earnings Call Transcript ↗
    Guidance rose as cost cuts from site closures started to take hold. 
    Via The Motley Fool
    Topics Earnings
    News headline image
    BioCryst Pharmaceuticals Q3 Earnings Call Highlights ↗
    BioCryst Pharmaceuticals (NASDAQ:BCRX) reported third-quarter results marked by growth in ORLADEYO revenue, higher profitability and progress across its hereditary angioedema, or HAE, portfolio, while... 
    Via MarketBeat
    Topics Earnings

    Performance

    52-Week Range 27.7% below 52-week high
    8.110
    6.2352W Low 11.2252W High
    1 Week 8.5% below 1-week high
    8.111W Low 8.861W High

    BioCryst Pharmaceuticals, Inc. - Common Stock (BCRX) traded between $6.23 and $11.22 over the past 52 weeks and last traded at $8.11, 27.7% below its 52-week high. Over the past week it ranged between $8.11 and $8.86.

    Past 12 Months
    -4.8%
    +0.1%
    -10.6%
    -8.2%
    +8.1%
    +20.0%
    1W -$0.41
    1M +$0.01
    3M -$0.96
    6M -$0.72
    YTD +$0.61
    1Y +$1.35

    BCRX was +20.0% over the past year, -8.2% over six months, +8.1% year to date, -4.8% in the last week.

    12 Months vs Market
    BCRX
    +20.0%
    DIA
    +13.5%
    SPY
    +12.7%
    QQQ
    +9.7%
    IWM
    +17.5%

    Over the past 12 months BCRX returned +20.0% versus DIA (Dow) +13.5%, SPY (S&P 500) +12.7%, QQQ (Nasdaq 100) +9.7% and IWM (Russell 2000) +17.5%.

    Volume & Liquidity 0.04× 3-mo avg
    Today 203,648 3-mo avg 4.8M
    1W
    5.8M
    1M
    5.2M
    3M
    4.8M
    6M
    4.8M
    YTD
    4.9M
    1Y
    4.8M

    BCRX most recently traded 203,648 shares against a 3-month average daily volume of 4.8M.

    More News

    Read More
    News headline image
    BioCryst Eyes $1B Rare-Disease Future Through External Innovation ↗
    Via MarketBeat
    BioCryst Pharmaceuticals (NASDAQ:BCRX) Passes Minervini Trend Template and High-Growth Momentum Screen ↗
    Via Chartmill
    BioCryst Pharmaceuticals (NASDAQ:BCRX) Surges on Q2 Earnings Beat ↗
    Via Chartmill
    BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Q1 2026 Results: Revenue Beat, EPS Miss ↗
    Via Chartmill
    BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Shatters Q4 2025 Estimates with Stellar Earnings Beat ↗
    Via Chartmill
    News headline image
    Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It ↗
    Via MarketBeat
    Topics Artificial Intelligence Bonds
    News headline image
    BioCryst (BCRX) Q2 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    BioCryst Pharmaceuticals Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    Why Are Retail Traders Going Gaga Over BioCryst Pharma Stock Today? ↗
    Via Stocktwits
    News headline image
    Earnings Scheduled For November 3, 2025 ↗
    Via Benzinga
    News headline image
    BioCryst Appoints David W. Jenkins as Chief Scientific Officer
    From BioCryst Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
    From BioCryst Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    BioCryst Pharmaceuticals Backs ORLADEYO Outlook as Navenibart Trial Advances ↗
    Via MarketBeat
    News headline image
    These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings ↗
    Via Benzinga
    News headline image
    BioCryst (BCRX) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Why Dyne Therapeutics Stock Was Crushing it This Week ↗
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
    From Astria Therapeutics, Inc.
    Via Business Wire
    News headline image
    BioCryst (BCRX) Q3 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Top Stocks With Earnings This Week: Joby, IonQ, AMD and More ↗
    Via Benzinga
    News headline image
    BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Posts Mixed Q3 2025 Results, Beats on EPS But Misses Revenue ↗
    Via Chartmill
    Topics Earnings
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sotherly Hotels Inc. (Nasdaq – SOHO), Hologic, Inc. (Nasdaq – HOLX), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hologic, Inc. (Nasdaq – HOLX), TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH), SWK Holdings Corporation (Nasdaq – SWKH)
    From Brodsky & Smith LLC
    Via GlobeNewswire

    Frequently Asked Questions

    Is BioCryst Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, BioCryst Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does BioCryst Pharmaceuticals, Inc. - Common Stock trade on?
    BioCryst Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for BioCryst Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for BioCryst Pharmaceuticals, Inc. - Common Stock is BCRX on the Nasdaq Stock Market
    What is the current price of BioCryst Pharmaceuticals, Inc. - Common Stock?
    The current price of BioCryst Pharmaceuticals, Inc. - Common Stock is 8.110
    When was BioCryst Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of BioCryst Pharmaceuticals, Inc. - Common Stock was at 11/05/26 09:37 AM ET
    What is the market capitalization of BioCryst Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of BioCryst Pharmaceuticals, Inc. - Common Stock is 1.51B
    How many shares of BioCryst Pharmaceuticals, Inc. - Common Stock are outstanding?
    BioCryst Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.